Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Authors: Clausen et al 

Journal/ Pre-PrintbioRxiv 

TagsCell Biology, Immunology/Immunity, Molecular biology, Virology 

Research Highlights

  1. The receptor binding domain of the SARS-CoV-2 spike protein contains binding sitefor both ACE2 and heparan sulfate (HS), and HS binding is required for ACE2 binding 

  1. Addition of exogenous heparin, heparin lyases and lung HS all inhibited spike protein binding and infection with S-pseudotype virus and SARS-CoV-2  

Summary

Docking studies of the receptor binding domain (RBD) of the SARS-CoV-2-S protein indicated a heparan sulfate (HS) binding site adjacent to that of ACE2. Spike ectodomains bound column-bound heparin and HS on several cell lines. ACE2 binding was dependent on HS: binding of spike ectodomains and infection with spike-bearing VSV and SARS-CoV-2 were inhibited by depleting HS availability by addition of HS lyases, unfractionated heparin, non-anticoagulent heparin, lung-derived HS or inactivation of a core HS synthetic enzyme, EXT1Mutations of enzymes involved in HS modification indicated that the RBD may recognise a specific pattern of sulfation on HS. 

Impact for SARS-CoV2/COVID19 research efforts  

Understand the virology and/or cell biology of SARS-CoV2/COVID19 - This study indicates that HS may act as a co-receptor for ACE2 binding by SARS-CoV-2 and presents a novel therapeutic strategy by targeting HS adhesion. 

Study Type  

  • In vitro study 

Strengths and limitations of the paper 

Novelty: This study shows that targeting HS binding by the spike protein can inhibit infection with SARS-CoV-2. An HS binding site on the RBD structure is suggested. It also suggests that level of cellular HS sulfation or sulfation pattern may contribute to ACE2 binding, which may contribute to susceptibility of patients to severe infection. 

Standing in the field:Previous literature has suggested cellular HS as a therapeutic target for COVID-19 and drugs such as suramin have been shown to have anti-viral properties. It has also been reported the SARS-CoV-2-S protein undergoes a conformational change upon HS binding. This study builds on current findings by showing that SARS-CoV-2 infection can be decreased by targeting HS binding. 

Appropriate statistics: Yes 

Viral model used:VSV pseudotype expressing S protein, SARS-CoV-1 and SARS-CoV-2 virus 

Translatability:No therapeutic or clinical work was done, but this study does further highlight HS as a viable target for COVID-19 treatment. 

Main limitations: In vitro work only